Priority 1 from the Kidney Transplant PSP
|Extra information provided by this PSP
|Original uncertainty examples
|How to treat acute and chronic antibody mediated rejection? What is the role of eculizumab in vascular rejection with an antibody mediated component? How should acute antibody-mediated rejection be treated? What is the best strategy for managing antibody mediated rejection?
|Clinicians x 4
|Outcomes to be measured
|Patient and graft survival, graft function, adverse events
|PSP unique ID
|Total number of uncertainties identified by this PSP.
|90 (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website)
|Date of priority setting workshop
|3 February 2016